Les sujets suivant sont pressentis pour les prochains appels du programme de financement Innovative Medecine Initiative qui sera lancé dans quelques mois:

Patient perspective elicitation on benefits and risks of medicinal products, supplementing benefitrisk assessments by regulators and HTAs (health technology assessments) from development through the entire life cycle

Development of a quantitative system toxicology (QST) platform

Diabetic kidney disease (DKD) biomarker idea Inflammation and Alzheimer’s disease (AD): modulating microglia function – focussing on TREM2 and CD33
Enabling magnetic encephalography (MEG) as a biomarker for diagnosis and disease progression in mild cognitive impairment (MCI) and Alzheimer’s disease (AD)
 Understanding the role of amyloid biomarkers in diagnosis, clinical management and treatment of patients with cognitive impairment

Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease

Bringing apolipoprotein E (APOE) biology to validated Alzheimer’s disease targets
All information regarding future IMI Call topics is indicative and subject to change.
Si l'un de ces sujets vous intéresse, veuillez prendre contact au plus tôt avec la cellule Europe. Nous sommes à votre disposition pour vous aider à monter votre consortium et déposer votre projet.
cellule.europe@innovonslareunion.com